Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2018-04-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report". It is issued by a certified public accounting firm (立信会计师事务所) and addresses the effectiveness of internal controls over financial reporting for the fiscal year ending December 31, 2017. The content includes auditor responsibilities, management responsibilities, and an audit opinion on internal control effectiveness. This is a standalone audit report focused on internal control over financial reporting, not a full annual report or financial statement. It matches the definition of an Audit Report / Information (AR) which includes standalone audit reports and applied accounting principles. The document length is about 5920 characters, sufficient to contain substantive audit content rather than a brief announcement or certification. Therefore, the correct classification is AR with high confidence.
2018-04-27 Chinese
关于对公司控股股东及其他关联方占用资金情况的专项审计说明
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by a certified public accounting firm (BDO) regarding the non-operating funds occupation and related party transactions of Jiangsu Sihuan Biological Co., Ltd. for the fiscal year 2017. It includes audit opinions, responsibilities of management and auditors, and detailed financial data related to related party fund usage. The document is titled as a '专项审计报告' (special audit report) and contains substantive financial data and audit conclusions. It is not a full annual report but a standalone audit report focusing on a specific audit area related to regulatory compliance and related party transactions. Therefore, it fits the category of Audit Report / Information (AR). The document length (7446 characters) and content confirm it is the report itself, not just an announcement or certification. Hence, the classification is AR with high confidence.
2018-04-27 Chinese
2018年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2018 年第一季度报告全文" which translates to "2018 First Quarter Report Full Text." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow analysis, shareholder information, and management statements. The presence of quarterly financial data and analysis, including comparisons to prior periods, confirms this is a quarterly financial report. The document length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2018
2018-04-27 Chinese
2018年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '江苏四环生物股份有限公司 2018 年第一季度报告正文' which translates to 'Jiangsu Sihuan Biological Co., Ltd. 2018 First Quarter Report'. It contains detailed financial data for the first quarter of 2018, including revenue, net profit, cash flow, shareholder information, and explanations of financial changes. The presence of quarterly financial statements and substantive financial data confirms it is a quarterly report. The document length is 5947 characters, which is sufficient to contain actual financial data rather than just an announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2018
2018-04-27 Chinese
2017年年度报告（已取消）
Annual Report Classification · 100% confidence The document is titled "江苏四环生物股份有限公司 2017 年年度报告全文" which translates to "Jiangsu Sihuan Bioengineering Co., Ltd. 2017 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, business analysis, management discussion, and financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. There are no indications that this is merely a notice or certification. The content includes audited financial figures, business segment analysis, and detailed disclosures consistent with a full annual report. Therefore, the document is classified as an Annual Report (10-K). FY 2017
2018-04-27 Chinese
关于核销应收账款的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the write-off of accounts receivable by Jiangsu Sihuan Bioengineering Co., Ltd. It details the board and supervisory committee meetings approving the write-off, references relevant accounting standards and regulatory guidelines, and includes opinions from the board, independent directors, and supervisory committee. The document is relatively short (1398 characters) and focuses on a specific financial event (write-off of receivables) rather than presenting comprehensive financial statements or a full report. It is not an annual or interim report, nor a detailed management discussion or earnings release. It is a regulatory announcement about a specific accounting action affecting the company's financials. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-04-27 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.